Navigation Links
VaxGen Issues Rebuttal to MedCap Letter
Date:3/25/2008

find such an outcome compelling when compared with the opportunities

represented by a combination with Raven.

5. Finally, although ISS notes MedCap's governance concerns, it neither

endorses them nor expresses any concerns over governance or the

process followed to date.

VaxGen also takes exception with ISS' recommendation regarding the 2008 Equity Incentive Plan. The text of ISS recommendation on the plan is as follows: "We commend the company for expressly forbidding the repricing of stock options under the plan. However, the estimated shareholder value transfer of the company's plans of 22 percent is above the allowable cap for this company of 20 percent."

VaxGen and its advisors have reviewed ISS' analysis and find it to be technically correct, as an analysis of the Plan as a stand-alone entity in the event of a negative vote on the merger proposal. Indeed, the management and Board of VaxGen believe that the 2008 Plan is moot in the event of a negative vote on the merger proposal. In practice, however, the plan is being proposed in the context of the proposed merger with Raven which, if approved, will nearly double VaxGen's shares outstanding. In this context, using ISS' own methodology, the proposed Plan would be well below ISS' allowable cap of 20%. VaxGen believes it would have been helpful for ISS to have noted this important contextual qualification to its analysis, in order that our stockholders not be left with the impression that VaxGen is proposing an excessive equity incentive plan.

Note: This letter contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding the anticipated benefits the proposed merger, the implications of a negative vote on the merger, and the estimated liquidation value to stockholders. These statements are subject to risks and uncertainties that could
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. ... and patient recruitment services. The core expertise of PRC Clinical is focused on ...
(Date:7/29/2015)... ... July 29, 2015 , ... Rainbow Scientific, Inc. ... announces the availability of BI’s line of human mesenchymal stem cell (hMSC) differentiation ... differentiation media offer a complete system for multipotency evaluation of hMSCs and reliable ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... 2015  PDL BioPharma, Inc. (PDL, or the Company) ... will release its second quarter 2015 financial results for ... 5, 2015, after market close. PDL,s management will host ... p.m. Eastern Time to discuss the financial results.  A ... via the webcast link on the PDL website. ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... HARBIN, China, April 7 /PRNewswire-Asia-FirstCall/ -- China Sky ... Company") (Nasdaq: CSKI ), a,leading fully ... Republic of China ("PRC"), today,announced that an extension ... its Annual Report on Form 10-K on March ...
... - European Operating Room Nurses Association (EORNA) to ... , Earlier today, Ansell Healthcare, ... it has taken a further step in supporting,the global ... After receiving earlier confirmation of ...
... type of probe that allows them to visualize single ... than existing methods. The tool will help scientists learn ... Techniques scientists currently use to image these transporters of ... need for synthetic RNA or a large number of ...
Cached Biology Technology:China Sky One Medical, Inc. Provides Update on Filing Form 10-K 2China Sky One Medical, Inc. Provides Update on Filing Form 10-K 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4Researchers develop new way to see single RNA molecules inside living cells 2Researchers develop new way to see single RNA molecules inside living cells 3
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... appearing in the forthcoming issue of The American Naturalist, ... M. Louda (all of the University of Nebraska, Lincoln) ... at the same rate. , Plant-insect ecologists typically ... or defective chemistry of plant tissues. However, the researchers ...
... speed healing at sites of injury - such as heart ... stroke - doctors would like to be able to hasten ... to "mobilize" patients' blood vessel-forming cells, called angiogenic cells, so ... at Washington University School of Medicine in St. Louis demonstrated ...
... the antibody that's the workhorse of the human immune ... the phagosomes that corral invading pathogens and the potent ... research, by Axel Nohturfft at Harvard University and colleagues ... of Technology, appears this week in the Proceedings of ...
Cached Biology News:Drug can quickly mobilize an army of cells to repair injury 2A key antibody, IgG, links cells' capture and disposal of germs 2
... HEK 293T cell line contains the b-lactamase ... response element (CRE). To obtain the cell ... HEK 293T cells by lentivirus. Subsequent flow ... to forskolin stimulation (Figure 1). The CellSensor ...
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Biology Products: